Funding

GelMEDIX

United States · Biotech

Develops regenerative therapies to restore vision by regenerating damaged retinal cells

Visit gelmedix.comFunding history

Funding history

1 round · 1 with disclosed amounts
AnnouncedRoundAmountInvestors
Seed$13MBeacon Angels — Role not disclosedBoston Harbor Angels — Role not disclosedHTL Biotechnology — Role not disclosedSafar Partners — Role not disclosedTiE Boston Angels — Role not disclosed

Investors

Beacon AngelsSeedBoston Harbor AngelsSeedHTL BiotechnologySeedSafar PartnersSeedTiE Boston AngelsSeed

Coverage

Feb 17, 2026GelMEDIX · Seed

Similar companies

Pathos AIClinical-stage drug developer using AI to select therapeutic assets and guide oncology trials.$237M · Series E
Star TherapeuticsBiotechnology company discovering and developing antibody therapies for diseases with significant unmet need.$200M · Private financing
iCUREXKagoshima medical-device company developing chitosan hydrogel materials for wound care, including the syringe-delivered Kitosla CX dressing.¥140M · Series A first close: equity and debt
Sourcesgelmedix.com ↗